Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.


Journal

The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821

Informations de publication

Date de publication:
03 2019
Historique:
received: 19 10 2018
revised: 16 11 2018
accepted: 16 11 2018
pubmed: 21 1 2019
medline: 22 5 2020
entrez: 21 1 2019
Statut: ppublish

Résumé

Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features. 345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort died at a median age of 25 years (range <1-59). Thyroidectomy was done before the age of 1 year in 20 patients, which led to long-term remission (ie, undetectable calcitonin level) in 15 (83%) of 18 individuals (2 patients died of causes unrelated to medullary thyroid carcinoma). Medullary thyroid carcinoma-specific survival curves did not show any significant difference between patients who had thyroidectomy before or after 1 year (comparison of survival curves by log-rank test: p=0·2; hazard ratio 0·35; 95% CI 0.07-1.74). However, there was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). There was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). In the other 318 patients who underwent thyroidectomy after 1 year of age, biochemical and structural remission was obtained in 47 (15%) of 318 individuals. Bilateral phaeochromocytoma was diagnosed in 156 (50%) of 313 patients by 28 years of age. Adrenal-sparing surgery was done in 31 patients: three (10%) of 31 patients had long-term recurrence, while normal adrenal function was obtained in 16 (62%) patients. All patients with available data (n=287) had at least one extra-endocrine feature, including 106 (56%) of 190 patients showing marfanoid body habitus, mucosal neuromas, and gastrointestinal signs. Thyroidectomy done at no later than 1 year of age is associated with a high probability of cure. The reality is that the majority of children with the syndrome will be diagnosed after this recommended age. Adrenal-sparing surgery is feasible in multiple endocrine neoplasia type 2B and affords a good chance for normal adrenal function. To improve the prognosis of such patients, it is imperative that every health-care provider be aware of the extra-endocrine signs and the natural history of this rare syndrome. The implications of this research include increasing awareness of the extra-endocrine symptoms and also recommendations for thyroidectomy before the age of 1 year. None.

Sections du résumé

BACKGROUND
Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection.
METHODS
This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features.
FINDINGS
345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort died at a median age of 25 years (range <1-59). Thyroidectomy was done before the age of 1 year in 20 patients, which led to long-term remission (ie, undetectable calcitonin level) in 15 (83%) of 18 individuals (2 patients died of causes unrelated to medullary thyroid carcinoma). Medullary thyroid carcinoma-specific survival curves did not show any significant difference between patients who had thyroidectomy before or after 1 year (comparison of survival curves by log-rank test: p=0·2; hazard ratio 0·35; 95% CI 0.07-1.74). However, there was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). There was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0·0001). In the other 318 patients who underwent thyroidectomy after 1 year of age, biochemical and structural remission was obtained in 47 (15%) of 318 individuals. Bilateral phaeochromocytoma was diagnosed in 156 (50%) of 313 patients by 28 years of age. Adrenal-sparing surgery was done in 31 patients: three (10%) of 31 patients had long-term recurrence, while normal adrenal function was obtained in 16 (62%) patients. All patients with available data (n=287) had at least one extra-endocrine feature, including 106 (56%) of 190 patients showing marfanoid body habitus, mucosal neuromas, and gastrointestinal signs.
INTERPRETATION
Thyroidectomy done at no later than 1 year of age is associated with a high probability of cure. The reality is that the majority of children with the syndrome will be diagnosed after this recommended age. Adrenal-sparing surgery is feasible in multiple endocrine neoplasia type 2B and affords a good chance for normal adrenal function. To improve the prognosis of such patients, it is imperative that every health-care provider be aware of the extra-endocrine signs and the natural history of this rare syndrome. The implications of this research include increasing awareness of the extra-endocrine symptoms and also recommendations for thyroidectomy before the age of 1 year.
FUNDING
None.

Identifiants

pubmed: 30660595
pii: S2213-8587(18)30336-X
doi: 10.1016/S2213-8587(18)30336-X
pmc: PMC8132299
mid: NIHMS1696171
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

213-220

Subventions

Organisme : Intramural NIH HHS
ID : ZIE BC011516
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : ErratumIn

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Références

Cancer. 2002 Jan 1;94(1):44-50
pubmed: 11815959
J Clin Endocrinol Metab. 2018 Jan 1;103(1):235-243
pubmed: 29077903
Endocr Relat Cancer. 2018 Feb;25(2):T29-T39
pubmed: 28698189
Surgery. 1994 Dec;116(6):1017-23
pubmed: 7985081
J Clin Endocrinol Metab. 2013 Nov;98(11):E1813-9
pubmed: 24030942
J Clin Endocrinol Metab. 2017 Jun 1;102(6):2069-2074
pubmed: 28323957
JAMA. 1996 Nov 20;276(19):1575-9
pubmed: 8918855
Ann Surg. 2014 Apr;259(4):800-6
pubmed: 23979292
Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1579-83
pubmed: 7906417
Eur J Endocrinol. 2013 Apr 15;168(5):683-7
pubmed: 23416954
Lancet Oncol. 2014 May;15(6):648-55
pubmed: 24745698
Hum Mol Genet. 1994 Feb;3(2):237-41
pubmed: 7911697
Surgery. 2008 Dec;144(6):1044-50; discussion 1050-3
pubmed: 19041016
Endocr Relat Cancer. 2017 Jul;24(7):L39-L42
pubmed: 28438782
Nat Rev Endocrinol. 2011 Aug 23;7(10):596-607
pubmed: 21862994
J Clin Endocrinol Metab. 2019 Jan 1;104(1):7-12
pubmed: 30113649
Thyroid. 2015 Jun;25(6):567-610
pubmed: 25810047
Surgery. 1995 Dec;118(6):936-42
pubmed: 7491537
Ann Surg Oncol. 2008 Jan;15(1):293-301
pubmed: 17963006

Auteurs

Frederic Castinetti (F)

Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale, Marseille Medical Genetics, Marseille, France; Assistance Publique-Hôpitaux de Marseille, Department of Endocrinology, Hôpital de la Conception, Centre de Référence des Maladies Rares de l'hypophyse, Marseille, France. Electronic address: frederic.castinetti@ap-hm.fr.

Steven G Waguespack (SG)

Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Andreas Machens (A)

Department of General, Visceral and Vascular Surgery, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany.

Shinya Uchino (S)

Noguchi Thyroid Clinic and Hospital Foundation, Beppu, Japan.

Kornelia Hasse-Lazar (K)

Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland.

Gabriella Sanso (G)

Centro de Investigaciones Endocrinológicas, "Dr César Bergadá", Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.

Tobias Else (T)

Division of Metabolism, Endocrinology, & Diabetes, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA.

Sarka Dvorakova (S)

Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.

Xiao Ping Qi (XP)

Departments of Oncologic and Urologic Surgery, The 117th People's Liberation Army Hospital, People's Liberation Army Hangzhou Clinical College, Anhui Medical University, Hangzhou, China.

Rossella Elisei (R)

Department of Endocrinology, University Hospital, Pisa, Italy.

Ana Luisa Maia (AL)

Thyroid Section, Endocrinology Division, Hospital de Cliínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

John Glod (J)

Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

Delmar Muniz Lourenço (DM)

Endocrine Genetics Unit, Endocrinology Division, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil; Endocrine Oncology Division, Institute of Cancer of the State of São Paulo, Faculty of Medicine of the University of São Paulo, São Paulo, Brazil.

Nuria Valdes (N)

Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias, Oviedo, Spain; Unit of Endocrinology, Nutrition, Diabetes and Obesity, Institute of Sanitary Research of Asturias, Oviedo, Spain.

Jes Mathiesen (J)

Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Nelson Wohllk (N)

Endocrine Section, Universidad de Chile, Hospital del Salvador, Santiago de Chile, Santiago, Chile.

Tushar R Bandgar (TR)

Department of Endocrinology, Seth G S Medical College, King Edward Memorial Hospital, Parel, Mumbai, India.

Delphine Drui (D)

L'Institut du thorax, Department of Endocrinology, Centre Hospitalier Universitaire Nantes, Nantes, France.

Marta Korbonits (M)

Department of Endocrinology, St Bartholomew's Hospital, London, UK; London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Maralyn R Druce (MR)

Department of Endocrinology, St Bartholomew's Hospital, London, UK; London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Caroline Brain (C)

Division of Endocrine Surgery, University College Hospital and Great Ormond Street Hospital, London, United Kingdom.

Tom Kurzawinski (T)

Division of Endocrine Surgery, University College Hospital and Great Ormond Street Hospital, London, United Kingdom.

Atila Patocs (A)

Hungarian Academy of Sciences and Semmelweis University, HSA-SE "Lendület" Hereditary Endocrine Tumour Research Group, Budapest, Hungary.

Maria Joao Bugalho (MJ)

Serviço de Endocrinologia, Diabetes e Metabolismo, Centro Hospitalar Universitário Lisboa Norte-Hospital Santa Maria, Lisboa, Portugal; Centro Académico de Medicina de Lisboa, Universidade Lisboa, Lisboa, Portugal.

Andre Lacroix (A)

Endocrine Division, Department of Medicine, Centre Hospitalier de l'Universite í de Montréal, Montreal, QC, Canada.

Philippe Caron (P)

Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Service d'Endocrinologie, Maladies métaboliques, Nutrition, Toulouse, France.

Patricia Fainstein-Day (P)

Endocrine and Nuclear Medicine Unit, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.

Francoise Borson Chazot (F)

Hospices Civils de Lyon, Fédération d'Endocrinologie, Université Claude Bernard Lyon 1, Lyon, France.

Marc Klein (M)

Department of Endocrinology, University Hospital, Nancy, France.

Thera P Links (TP)

Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.

Claudio Letizia (C)

Department of Internal Medicine and Medical Specialties, Sapienza University of Rome, Rome, Italy.

Laura Fugazzola (L)

Division of Endocrine and Metabolic Diseases, Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Auxologico Italiano, University of Milan, Milan, Italy; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

Olivier Chabre (O)

Centre Hospitalier Universitaire de Grenoble, Hôpital Albert Michallon, Service d'Endocrinologie-Diabétologie-Nutrition, Grenoble, France.

Letizia Canu (L)

Department of Experimental and Clinical Biomedical Sciences, Endocrinology Unit, University of Florence, Florence, Italy.

Regis Cohen (R)

Endocrinologie et Métabolismes, Centre Hospitalier de Saint Denis, Saint-Denis, France.

Antoine Tabarin (A)

Centre Hospitalier Universitaire de Bordeaux, Hôpital du Haut Lévêque, Service d'Endocrinologie-Diabétologie et Maladies Métaboliques, Pessac, France.

Anita Spehar Uroic (A)

Department of Pediatrics, University Hospital Centre Zagreb, Zagreb, Croatia.

Dominique Maiter (D)

Service d'Endocrinologie et Nutrition, Cliniques Universitaires Saint-Luc, Universite Catholique de Louvain, Brussels, Belgium.

Sandrine Laboureau (S)

Department of Endocrinology, Diabetes and Nutrition, Reference Centre of Rare Thyroid Disease, Hospital of Angers, Angers, France.

Caterina Mian (C)

Operative Unit of the Endocrinology, Department of Medicine, University of Padua, Padua, Italy.

Mariola Peczkowska (M)

Department of Hypertension, Institute of Cardiology, Warsaw, Poland.

Frederic Sebag (F)

Department of Endocrine Surgery, La Conception Hospital, Marseille, France.

Thierry Brue (T)

Aix-Marseille Université, Institut National de la Santé et de la Recherche Médicale, Marseille Medical Genetics, Marseille, France; Assistance Publique-Hôpitaux de Marseille, Department of Endocrinology, Hôpital de la Conception, Centre de Référence des Maladies Rares de l'hypophyse, Marseille, France.

Delphine Mirebeau-Prunier (D)

Département de Biochimie et Génétique, Centre Hospitalier Universitaire d'Angers, Angers, France.

Laurence Leclerc (L)

Centre Hospitalier Régional Universitaire de Lille, Hopital Huriez, Service d'Endocrinologie, Lille, France.

Birke Bausch (B)

Section for Preventive Medicine, Department of Nephrology and General Medicine, Freiburg, Germany.

Amandine Berdelou (A)

Endocrine Oncology, Institut Gustave Roussy Ecole Doctorale de Cancerologie, Villejuif, France.

Akihiro Sukurai (A)

Department of Medical Genetics and Genomics, Sapporo Medical University School of Medicine, Chuo-ku, Sapporo, Hokkaido, Japan.

Petr Vlcek (P)

Department of Nuclear Medicine and Endocrinology, Second Faculty of Medicine, Charles University, Prague, Czech Republic; Motol University Hospital, Prague, Czech Republic.

Jolanta Krajewska (J)

Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland.

Marta Barontini (M)

Centro de Investigaciones Endocrinológicas, "Dr César Bergadá", Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina.

Carla Vaz Ferreira Vargas (C)

Thyroid Section, Endocrinology Division, Hospital de Cliínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Laura Valerio (L)

Department of Endocrinology, University Hospital, Pisa, Italy.

Lucieli Ceolin (L)

Thyroid Section, Endocrinology Division, Hospital de Cliínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.

Srivandana Akshintala (S)

Department of Pediatrics, New York University Langone Medical Center, New York, NY, USA.

Ana Hoff (A)

Endocrine Genetics Unit, Endocrinology Division, Hospital das Clínicas, University of São Paulo School of Medicine, São Paulo, Brazil; Endocrine Oncology Division, Institute of Cancer of the State of São Paulo, Faculty of Medicine of the University of São Paulo, São Paulo, Brazil.

Christian Godballe (C)

Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Barbara Jarzab (B)

Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Gliwice, Poland.

Camilo Jimenez (C)

Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Charis Eng (C)

Genomic Medicine Institute, Lerner Research Institute and Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Tsuneo Imai (T)

Department of Breast and Endocrine Surgery, National Hospital Organization Higashinagoya National Hospital, Nagoya, Japan.

Martin Schlumberger (M)

Endocrine Oncology, Institut Gustave Roussy Ecole Doctorale de Cancerologie, Villejuif, France.

Elizabeth Grubbs (E)

Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Henning Dralle (H)

Section of Endocrine Surgery, Department of General, Visceral, and Transplantation Surgery, University Hospital Essen, Essen, Germany.

Hartmut P Neumann (HP)

Section for Preventive Medicine, Department of Nephrology and General Medicine, Freiburg, Germany.

Eric Baudin (E)

Endocrine Oncology, Institut Gustave Roussy Ecole Doctorale de Cancerologie, Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH